Table 1.
Multiple treatments targeting the IL-6, IL-6R and IL-6-related signaling pathways.
| Target | Inhibitor/drug | Effect | References |
|---|---|---|---|
| IL-6/IL-6R | Madindoline A | Inhibits the dimerization of IL-6/IL-6R/gpl30 trimeric complexes | (97) |
| Siltuximab | Neutralize the activity of IL-6 | (98) | |
| Humanized anti-IL-6 antibody (ALD518) | Neutralize the activity of IL-6 | (100, 101) | |
| CNTO-136 | Neutralize the activity of IL-6 | (99) | |
| Tocilizumab | inhibits the binding of IL-6 to IL-6R | (102) | |
| JAK | AG490 | Inhibit the activity of JAK | (106) |
| Ruxolitinib | Inhibit the activity of JAK | (105) | |
| AZG1480, ZAD9150 | Inhibit the activity of JAK | (110, 111) | |
| TG101209 | Inhibit the activity of JAK | (106) | |
| STAT3 | S31-201 | inhibits the activity of STAT3 | (110) |
| C188-9 | Inhibit the phosphorylation of STAT3 | (111) | |
| Curcumin | Inhibit the phosphorylation of STAT3 | (112) | |
| LLL12 | Inhibit phosphorylation and nuclear translocation of STAT3 | (109) | |
| OPB-31121 | Inhibit the phosphorylation of Tyr705 | (111) | |
| AZD9150 | Inhibit the phosphorylation of STAT3 | (112) | |
| S3I-1757 | Destroy the structure of STAT3 dimer by binding to site Tyr705 | (114) | |
| STA-21 | Inhibit the dimerization of STAT3 and binding to DNA | (115) |